John Wagstaff
0000-0002-1140-5981
Swansea University
146 papers found
Refreshing results…
Tumor angiogenesis modulates leukocyte-vessel wall interactions in Vivo by reducing endothelial adhesion molecule expression
The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models.
Flow cytometric quantification of tumour endothelial cells; an objective alternative for microvessel density assessment
Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy
A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma
Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies.
The antiangiogenic properties of bactericidal/permeability-increasing protein (BPI)
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients
[Angiogenesis and the regulation of antitumor defense]
Dendritic cells: a novel therapeutic modality.
Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.
Management of Stage III Breast Cancer
Interleukin-2 therapy does not exacerbate multiple sclerosis
Effects of Chemotherapy on Pathologic and Biologic Characteristics of Locally Advanced Breast Cancer
Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer
T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma.
Interleukin-6 Downregulates Factor XII Production by Human Hepatoma Cell Line (HepG2)
Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.
Missing publications? Search for publications with a matching author name.